CD44 and head and neck squamous cell carcinoma: For example, MUC1-targeted CAR-T cells have shown potent cytotoxic activity against HNSCC cells in vitro, while CD44-targeted CAR-Ts have demonstrated efficacy in treating aggressive tumors.